Applied Biologics
Applied Biologics is a privately held, Scottsdale-based regenerative medicine company that develops, manufactures, and sells the XWRAP amniotic membrane allograft for chronic and surgical wounds, while advancing BIOxHEAL (Phase 3 for diabetic foot ulcers) and a preclinical osteoarthritis gene therapy program through its GMP facility.
- Company typePrivate
- Founded2010
- HeadquartersScottsdale, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Applied Biologics does
Applied Biologics is a privately held, fully-integrated life sciences company founded in 2010 and headquartered in Scottsdale, Arizona, that develops, manufactures, and distributes regenerative medicine products focused on wound care and surgical tissue management. The company's commercial core is XWRAP, a dehydrated amniotic membrane-derived allograft available in six specialized formulations (including XWRAP Plus and XWRAP Dual) used as a protective barrier and covering for acute and chronic wounds such as diabetic, venous, arterial, and pressure ulcers, as well as surgical and burn sites. The underlying platform is the proprietary ECM Preservation Technology, an aseptic recovery and processing method that preserves extracellular matrix integrity and biologic activity, with all products manufactured domestically in a GMP-certified facility and screened in a CLIA-certified laboratory meeting or exceeding AATB criteria.
The company is advancing a multi-asset pipeline led by BIOxHEAL, an investigational biologic for chronic wound treatment that received FDA IND clearance in June 2026 to enter Phase 3 clinical development for diabetic foot ulcers, with GMP clinical lots successfully manufactured in July 2026. A second pipeline program targets disease-modifying osteoarthritis (DMOAD) via gene therapy and is in preclinical development, with a first research construct manufactured in July 2026. Applied Biologics generates revenue primarily through direct sales of XWRAP via a national commercial organization targeting wound care centers, surgery, hospitals, physician offices, and integrated health systems, supplemented by enterprise health system purchase agreements (Providence Health & Services) and federal supply channel access (VA Federal Supply Schedule, up to 20 years).
Commercially, the company pursues an evidence-led go-to-market backed by the CAMPX randomized controlled trial (222 subjects, 23 sites; 31% closure vs 18% standard of care, p=0.023) published in the International Journal of Tissue Repair, plus surgeon education programs across peripheral nerve, tendon, ligament, orthopedic, plastic and reconstructive, spine, and sports medicine specialties. The company operates at a scale of 11-50 employees, with leadership under CEO Edward Britt, and has launched an Applied Biologics Venture Capital investment arm focused on early and growth-stage biotechnology companies.
Applied Biologics firmographics
Firmographics- Name
- Applied Biologics
- Legal name
- Applied Biologics
- Website
- https://appliedbiologics.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Applied Biologics is a privately held, Scottsdale-based regenerative medicine company that develops, manufactures, and sells the XWRAP amniotic membrane allograft for chronic and surgical wounds, while advancing BIOxHEAL (Phase 3 for diabetic foot ulcers) and a preclinical osteoarthritis gene therapy program through its GMP facility.
- Ownership category
- akta.pro rank
Applied Biologics industry classification
Industry- Product category
- Regenerative Medicine Biologics
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Wound Care, Ostomy & Enteral Nutrition Supplies (HSABAKAI)
Keywords
Where Applied Biologics is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Applied Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- XWRAP Product Sales: Applied Biologics generates revenue through the sale of its placental-derived wound care products including XWRAP and its specialized formulations. The company manufactures and distributes biologic products domestically from its Scottsdale, Arizona facility.
- Regenerative Medicine Pipeline: Future revenue potential from BIOxHEAL and osteoarthritis gene therapy program as products advance through clinical development phases toward regulatory approval and commercialization.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Applied Biologics product offering
Product offeringCore offering
Applied Biologics researches, develops, manufactures, and distributes placental-derived regenerative medicine products. Its core commercial product is XWRAP®, a dehydrated amniotic membrane allograft offered in six specialized formulations for use as a protective barrier and wound covering across acute and chronic wounds. The pipeline includes BIOxHEAL (an FDA Phase 3-cleared biologic for diabetic foot ulcers) and a preclinical osteoarthritis gene therapy program, all produced at its GMP facility in Scottsdale, Arizona.
Product overview
Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing, and distribution of regenerative medicine products. The company operates a GMP manufacturing facility in Scottsdale, Arizona and has developed a portfolio of biologic products. The core commercial product is XWRAP, a dehydrated amniotic membrane-derived allograft for wound care available in multiple formulations. The pipeline includes BIOxHEAL, an investigational biologic for chronic wounds with FDA Phase 3 clearance, and an Osteoarthritis Gene Therapy program in preclinical development. The company also launched Applied Biologics Venture Capital as an investment arm supporting biotechnology companies.
Differentiator
Problem solved
Functional benefit
Brands
- XWRAP: Dehydrated amniotic membrane-derived allograft for use as a protective barrier and wound covering for acute and chronic wounds. Available in six specialized formulations: XWRAP, XWRAP Plus, XWRAP Dual.
- BIOxHEAL
- ECM Preservation Technology
- Applied Commercial Success Program
Products and services
- XWRAP® Amniotic Membrane-derived Allograft Dehydrated amniotic membrane allograft used as a protective barrier and wound covering for acute and chronic wounds including diabetic, venous, arterial, pressure ulcers, traumatic wounds, burns, surgical and Mohs surgery sites. Available in six specialized formulations (including XWRAP, XWRAP Plus, and XWRAP Dual) addressing specific wound healing challenges across diverse clinical applications.
- BIOxHEAL Investigational biologic therapy targeting diabetic foot ulcers and chronic wounds. FDA-cleared for Phase 3 clinical development (June 2026), representing a novel biologic approach to chronic wound treatment.
- Osteoarthritis Gene Therapy Program Preclinical disease-modifying osteoarthritis (DMOAD) gene therapy program focused on developing therapies to address biologic processes contributing to cartilage degeneration, joint deterioration, and disease progression.
Quantifiable outcome
- 31% complete wound closure with XWRAP plus standard of care versus 18% with standard of care alone (Intent-to-Treat analysis, p=0.023)
- +3 more outcomes
Companies that use Applied Biologics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Applied Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Applied Biologics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Providence Health & ServicescoreExtended longstanding system-wide purchase agreement for XWRAP placental-derived wound cover. Agreement builds on relationship initiated in 2015 and supports continued access to XWRAP across Providence's network of hospitals, outpatient facilities, and affiliated healthcare organizations throughout the United States. Health system partnerships remain a key component of Applied Biologics' long-term commercial strategy and national market access initiatives.
- Professional Education and Research Institute (PERI)coreServing as contract research organization responsible for data management, statistical analysis, and medical writing for multi-center retrospective real-world outcomes study of XWRAP across multiple chronic wound types. Study collecting de-identified electronic medical record data from 10-15 high-volume wound care centers across the United States. Findings expected to support peer-reviewed publications and future reimbursement and regulatory evidence generation.
- SerenaGroupcoreLeading wound care research organization collaborating on CAMPX randomized controlled clinical trial. Trial conducted across 23 research sites throughout the United States evaluating XWRAP in management of chronic diabetic foot ulcers. Principal Investigator Dr. Thomas Serena leads the study with enrollment completion and final study closeout activities ongoing.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Applied Biologics competitors and assessment
Company assessmentDirect peers
- MiMedx Group: MiMedx is a direct competitor in placental-derived allografts (e.g., EpiFix, AmnioFix) used for chronic wound care and surgical applications, operating in the same amniotic membrane category as Applied Biologics' XWRAP with overlapping physician call points and IDN contracting strategy.
- Organogenesis: Organogenesis is a direct competitor in regenerative medicine wound care biologics (Apligraf, Dermagraft, PuraPly), serving the same chronic wound care and surgical market segments with comparable IDN/GPO contracting models.
- Vericel: Vericel is a regenerative medicine peer developing cell-based therapies for wound care (e.g., Epicel for burns) with a similar biologic manufacturing and clinical development profile, making it directly comparable to Applied Biologics' BIOxHEAL and placental allograft strategy.
Broad incumbents
- Integra LifeSciences: Integra is a broad regenerative medicine and wound care incumbent with skin substitutes and tissue technologies serving similar hospital and wound care center customers as Applied Biologics, though across a much wider product portfolio.
- Smith+Nephew: Smith+Nephew is a broad wound care incumbent with advanced wound management, biologics, and NPWT portfolios serving hospitals, ambulatory surgery centers, and integrated delivery networks that overlap with Applied Biologics' commercial targets.
- ConvaTec: ConvaTec is a broad wound care incumbent with advanced wound dressings, skin substitutes (e.g., InnovaMatrix), and ostomy products targeting the same chronic wound care clinicians and health system customers as Applied Biologics.
- Coloplast: Coloplast is a broad wound care and ostomy incumbent with advanced wound care dressings and biologic skin substitutes serving overlapping hospital, wound care clinic, and home health channels in the U.S. market.
- Mölnlycke Health Care: Mölnlycke is a broad wound care and surgical incumbent with advanced dressings, negative pressure wound therapy, and biologic products targeting the same hospitals, ambulatory surgery centers, and integrated delivery networks as Applied Biologics.
- 3M Health Care (formerly Acelity/KCI): 3M Health Care (including the former KCI/Acelity business) is a broad wound care incumbent with V.A.C. NPWT systems and adjunctive wound care products serving the same hospital, IDN, and VA customers that are central to Applied Biologics' commercial strategy.
Emerging players
- Aroa Biosurgery: Aroa Biosurgery is an emerging regenerative medicine player with ovine-derived extracellular matrix wound care products (e.g., Endoform, Myriad) competing in chronic wound management with comparable biologic positioning to XWRAP.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Applied Biologics social profiles
Digital presenceApplied Biologics compliance and trust
Trust signalCompliance3 records
Applied Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Applied Biologics leadership team
Management profileNumber of profiles
Profiles3 records
Applied Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Applied Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Applied Biologics
What does Applied Biologics do?
Applied Biologics researches, develops, manufactures, and distributes placental-derived regenerative medicine products. Its core commercial product is XWRAP®, a dehydrated amniotic membrane allograft offered in six specialized formulations for use as a protective barrier and wound covering across acute and chronic wounds. The pipeline includes BIOxHEAL (an FDA Phase 3-cleared biologic for diabetic foot ulcers) and a preclinical osteoarthritis gene therapy program, all produced at its GMP facility in Scottsdale, Arizona.
Is Applied Biologics a public or private company?
Applied Biologics is a private company. It is classified as unknown and is currently operating.
When was Applied Biologics founded?
Applied Biologics was founded in 2010. It employs 11 to 50 people.
Where is Applied Biologics based?
Applied Biologics is headquartered in Scottsdale, United States, in the North America region.
How does Applied Biologics make money?
Two revenue lines are on record. XWRAP Product Sales are the primary driver. The others are regenerative Medicine Pipeline.
Who are Applied Biologics's main competitors?
Direct peers on record are MiMedx Group, Organogenesis and Vericel. Broad incumbents are Integra LifeSciences, Smith+Nephew, ConvaTec, Coloplast, Mölnlycke Health Care and 3M Health Care (formerly Acelity/KCI). Aroa Biosurgery is listed as an emerging player.
Does Applied Biologics have an API?
No public API is recorded for Applied Biologics.
What industry is Applied Biologics in?
Applied Biologics's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HSABAKAI, Wound Care, Ostomy & Enteral Nutrition Supplies. Its NAICS code is 339113 and its SIC code is 3842.